Robert Getts

Robert Getts serves as Chief Technology Officer at Code BioTherapeutics. Code BioTherapeutics operates in the research sector with approximately 37.0 employees. Code BioTherapeutics generates annual revenue of 100000.0. To date, Code BioTherapeutics has raised 85000000.0 in total funding, with the most recent round being Series A.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • We have verified contacts for 2 executives at Code BioTherapeutics.
• • Our database includes 201,468 c suite-level executives.

Route 53 Outlook Microsoft Office 365 Google Cloud Hosting Varnish Google Tag Manager Google Analytics Mobile Friendly Wix Viewpoint

biotechnology research genetic medicine 3dna delivery platform non-viral delivery gene therapy targeted delivery rnai precision medicine bioavailability modular delivery duchenne muscular dystrophy (dmd) cell specific targeting re-dosable genetic medicines immunogenicity dose related toxicity off-target effects therapeutic potency synthetic dna genetic disorders rare diseases gene editing vector manufacturing therapeutic cargo biodistribution cell internalization safety profiles multivalent structure peptide targeting nanotechnology preclinical development patient-specific therapy biopharmaceutical research innovative drug delivery modular manufacturing gene constructs chronic dosing therapeutic efficacy drug development translational medicine collaboration in drug discovery clinical research disease modulation tissue specific promoter biosafety target identification molecular delivery systems next generation therapeutics advanced gene therapy solutions forbidden targets

AT

Alex Tracy Chief Technical Officer at Code BioTherapeutics

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

Outreach Guidance — research Sector

Executives like Robert Getts in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Code BioTherapeutics.

Robert Getts's Position in the MessageCEO Database

• •Robert Getts is 1 of 2 verified executive contacts we track at Code BioTherapeutics.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •36 verified contacts work at research companies in the 37.0 employee range (same size as Code BioTherapeutics).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated August 2026.

How do I reach Robert Getts directly?

Robert Getts's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Technology Officer at Code BioTherapeutics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Robert Getts work for?

Robert Getts is Chief Technology Officer at Code BioTherapeutics, a company in the research sector with 37.0 employees.

Can I pitch or sell to Robert Getts?

As Chief Technology Officer at Code BioTherapeutics, Robert Getts is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Robert Getts directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Robert Getts in?

Robert Getts works in the research industry as Chief Technology Officer at Code BioTherapeutics. MessageCEO provides verified contact information for executives across all major industries.

Is Robert Getts's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Robert Getts's profile is kept up-to-date with the latest available information.

Last updated: August 1, 2026